- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2014
- Public Summary Document (PSD) July 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2014 PBAC Meeting - Word
Golimumab; infliximab; ustekinumab – July 2014
Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®;Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial, Stelara®; Janssen-Cilag Pty Ltd
Last updated
8 November 2023